Mount Sinai School of Medicine conducting clinical trials with gene therapy for colorectal cancer

Researchers at Mount Sinai School of Medicine began clinical trials on a unique and promising approach to gene therapy for colorectal cancer. The study uses genes to make the cancer cells look foreign to the body's immune system, which will then attack and destroy the cancer.

Colorectal cancer is the second leading cancer killer in the United States. The American Cancer Society estimates that 147,500 cases of colorectal cancer will be diagnosed in the country in 2003 and 57,000 people will die from the disease.

In experiments with laboratory animals, Mount Sinai researchers have demonstrated that their approach to gene therapy, known as tumor immunization, extended life in all animals tested and wiped out cancer entirely in up to 20% of animals whose cancer had spread from the colon to the liver.

"Cancer cells are able to grow unimpeded by the body's defenses because they look very similar to healthy cells, with only very subtle differences that pass under the radar screen of the body's immune cells," said Savio Woo, PhD, Director of the Carl C. Icahn Center for Gene Therapy and Molecular Medicine at Mount Sinai School of Medicine. "We use gene transfer technology to insert a gene into the cancer cells that makes them visible to the body's natural immune defenses."

The method of tumor immunization which Mount Sinai researchers developed involves transferring a gene that codes for Interleukin-12 (IL12) into cancer cells directly in the patient's tumor. IL12 is a protein that is not normally produced by cancer cells. When the cancer cells produce this protein as a result of gene transfer it acts as a signal to a special class of white blood cells of the immune system telling them, "These cancer cells are dangerous. Come over here and destroy them."

The laboratory and animal studies conducted by Dr. Woo and colleagues have provided evidence that delivering the IL12 gene to cancer cells can trigger a targeted immune response that destroy

Contact: Debra Kaplan
The Mount Sinai Hospital / Mount Sinai School of Medicine

Page: 1 2

Related biology news :

1. Mount Holyoke College series examines advances in human reproductive technologies
2. Mountain cloud forests imperiled by lowland deforestation, says Science study
3. Yale researchers solve structure of the ribosome: groundbreaking achievement like climbing Mount Everest
4. Cadmium toxicity threatening wildlife in Rocky Mountains
5. Extra oxygen improves survival odds for climbers on Mount Everest, K2
6. Biological legacies a key of ecological rebirth after Mount St. Helens eruption
7. Mountains of variables: The effect of landscape features on atmospheric deposition
8. Chytrid fungus associated with boreal toad deaths in Rocky Mountains
9. Mountain Lake Hotel places environmental book in rooms
10. USGS Study Confirms An Urban Air-Pollution Problem At Mount Rainier National Park
11. Evidence Mounts Against Maintstream Dogma In Embryology, Could Shed New Light On Neurological Defects

Post Your Comments:

(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology:
Cached News: